La ATC es una alternativa válida en el TCI

Left Main Coronary Artery Percutaneous Coronary Intervention: Evolution and Results over Time

Left main coronary artery percutaneous coronary intervention (LMCA PCI) is a treatment option that is increasingly used in our setting. One of the reasons for choosing this therapeutic strategy is the improvements in devices and techniques. However, the long-term results of LMCA PCI are not well established. The aim of this retrospective study was to<a href="https://solaci.org/en/2023/01/31/left-main-coronary-artery-percutaneous-coronary-intervention-evolution-and-results-over-time/" title="Read more" >...</a>

FRAME-AMI: FFR vs. Angiography of Non-Culprit Vessel in ACS

This study compared fractional flow reserve (FFR) vs. angiography to guide the angioplasty of non-culprit vessels in patients with acute coronary syndrome (ACS) and multivessel disease. Landmark studies such as COMPLETE, COMPARE-ACUTE and DANAMI-3-PRIMULTI have demonstrated the prognostic value of revascularization (after treatment of the artery responsible for the ACS) of non-culprit arteries with respect<a href="https://solaci.org/en/2023/01/25/frame-ami-ffr-vs-angiography-of-non-culprit-vessel-in-acs/" title="Read more" >...</a>

Evaluación funcional de las estenosis coronarias en la vida real: todavía no hicimos el click.

Left Main Coronary Artery PCI Using State-of-the-Art Zotarolimus-Eluting Stents

Percutaneous coronary intervention (PCI) to the left main coronary artery (LMCA) with drug-eluting stent implantation is currently a major challenge due to the size of the vessel, the compromise of a bifurcation lesion in important branches, and the potential risk of complications. Available information on LMCA PCI comes from studies where DES stents were implanted<a href="https://solaci.org/en/2023/01/18/left-main-coronary-artery-pci-using-state-of-the-art-zotarolimus-eluting-stents/" title="Read more" >...</a>

ATC sobre arterias nativas o puentes venosos, ¿cuál tiene mejor pronóstico?

Real-World Revascularization Strategy for Left Main Coronary Artery: Surgery or PCI?

There are many current randomized trials comparing percutaneous coronary intervention (PCI) with myocardial revascularization surgery (MRS) for the treatment of left main coronary artery disease (LMCAD). In the European Society of Cardiology guidelines, PCI is classified as Ia (LMCAD with low-complexity coronary disease) or IIa indication (intermediate complexity), whereas, according to the American Heart Association<a href="https://solaci.org/en/2023/01/11/real-world-revascularization-strategy-for-left-main-coronary-artery-surgery-or-pci/" title="Read more" >...</a>

The most read articles in interventional cardiology

Interventional cardiology: the most read articles of 2022 in solaci.org

Discover the most read scientific articles on interventional cardiology of 2022 in our website. The FDA Approves Intravascular Lithotripsy for Calcified Lesions The US Food and Drug Administration (FDA) has cleared the shockwave lithotripsy system to treat severely calcified plaque lesions. Is Epinephrine Superior to Adenosine in No-REFLOW? In patients with acute coronary syndrome, no-reflow prevalence is 32%. Different drugs—such as adenosine, verapamil,<a href="https://solaci.org/en/2023/01/05/interventional-cardiology-the-most-read-articles-of-2022-in-solaci-org/" title="Read more" >...</a>

Buen desempeño de la Sapien 3 en “trabajos” para los que no está diseñada

Real-World Results of Different Devices for TAVR

Transcatheter aortic valve replacement (TAVR) keeps growing in terms of the development of new devices, more extensive operator experience, and enhanced procedure planning. Nowadays, there are multiple device options, which depend on patient characteristics and operator experience. Two-arm studies compared these devices, analyzing the potential benefits of a certain valve over the others. This multicenter<a href="https://solaci.org/en/2023/01/04/real-world-results-of-different-devices-for-tavr/" title="Read more" >...</a>

Aspirina o clopidogrel post TAVI: Guías y estudios llenos de contradicciones

Is Clopidogrel Monotherapy Safe After a Month of Dual Antiplatelet Therapy in Diabetic Patients?

Currently, many randomized studies have suggested that short-term dual antiplatelet therapy (DAPT) followed by monotherapy reduces bleeding without increasing major cardiovascular events after percutaneous coronary intervention (PCI). A meta-analysis of six randomized studies has shown this benefit using ticagrelor monotherapy after short DAPT. However, there is no data on the results of clopidogrel monotherapy. Researchers<a href="https://solaci.org/en/2022/12/27/is-clopidogrel-monotherapy-safe-after-a-month-of-dual-antiplatelet-therapy-in-diabetic-patients/" title="Read more" >...</a>

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

Ticagrelor or Prasugrel Post-PCI in Daily Practice Patients

The ISAR-REACT 5 showed a significant reduction in the composite outcome of death, acute myocardial infarction (AMI), or stroke when using prasugrel vs. ticagrelor in patients with acute coronary syndrome (ACS), mainly at the expense of an AMI reduction. While this study changed clinical practice, it has stirred some criticism regarding certain methodological aspects, such<a href="https://solaci.org/en/2022/12/19/ticagrelor-or-prasugrel-post-pci-in-daily-practice-patients/" title="Read more" >...</a>

Valve-in-Valve Shows Good Evolution after 2 Years

The degeneration of bioprostheses in aortic position occurs at approximately after 10 to 15 years. In this scenario, the treatment of choice used to be redo surgery, but with the evolution of transcatheter aortic valve replacement (TAVR), it became a valid alternative with a level IIa B evidence. While there are currently multiple analyses of<a href="https://solaci.org/en/2022/12/02/valve-in-valve-shows-good-evolution-after-2-years/" title="Read more" >...</a>

¿Hay diferencias entre mujeres y hombres luego de una intervención percutánea?

Sex Differences According to Thrombus Burden in STEMI Patients

Many studies have shown there is higher mortality and complications among women after acute myocardial infarction (AMI) vs. men, especially after 30 days. Even though the mechanism driving higher mortality remains uncertain, recent studies have seen differences in thrombus formation with increased platelet count among women. In STEMI patients, intracoronary thrombus burden is a predictor<a href="https://solaci.org/en/2022/11/18/sex-differences-according-to-thrombus-burden-in-stemi-patients/" title="Read more" >...</a>